Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer

Muhammad Ary Zucha, Alexander T H Wu, Wei Hwa Lee, Liang Shun Wang, Wan Wan Lin, Chiou Chung Yuan, Chi-Tai Yeh

研究成果: 雜誌貢獻文章

23 引文 斯高帕斯(Scopus)

摘要

According to a Prognoscan database, upregulation of Bruton's tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistant. We next treated CSCs and non- CSCs by a combination of ibrutinib and cisplatin. We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer.
原文英語
頁(從 - 到)13255-13268
頁數14
期刊Oncotarget
6
發行號15
出版狀態已發佈 - 2015

ASJC Scopus subject areas

  • Oncology

指紋 深入研究「Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer」主題。共同形成了獨特的指紋。

  • 引用此